fig2
Figure 2. Hsa_circ_0020714 may act as a biomarker for resistance to anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) patients. (A) Lung adenocarcinoma. (B) Lung squamous cell carcinoma. **P < 0.01.
Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Navigation
Committee on Publication Ethics
https://members.publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
